• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Debiopharm Group

edit

Debiopharm Groupâ„¢ is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Recent Milestones

edit

• 
  Debiopharm Group invested in urturn. (5/22/13)
  Posted 5/22/13 at 6:16am via techcrunch.com
• 
  Debiopharm Group invested in Spinomix. (1/9/13)
  Posted 1/9/13 at 8:49pm via finsmes.com
• 
  Debiopharm Group invested in Agendia. (5/31/12)
  Posted 5/31/12 at 5:53am via bizjournals.com
• 
  Debiopharm Group invested in Biocartis. (11/17/11)
  Posted 11/17/11 at 6:17pm via finsmes.com
• 
  Debiopharm Group invested in Biocartis. (4/8/10)
  Posted 7/8/10 at 8:39pm via biocartis.com
• 
  Debiopharm Group invested in Curis. (2/12/10)
  Posted 1/22/10 at 4:38pm via fiercebiotech.com

Videos

Screenshots

edit

Above: Debiopharm Group Screenshot -- #1
Uploaded: 11/25/10

Sources

1. Urturn Raises $13.4M Series A, Led By Balderton, For Its Social Expressions Platform That Lets Teens Create Memes & Movements (techcrunch.com) [edit]
2. Spinomix Closes $3M Series A Equity Funding (finsmes.com) [edit]
3. Agendia Raises $65 Million in a Private Round of Equity Financing (bizjournals.com) [edit]
4. Biocartis Completes €71M Series C Equity Funding (finsmes.com) [edit]
5. Biocartis raises €30 million in Series ‘B' financing round (biocartis.com) [edit]
6. Curis gets $8M milestone from Debiopharm (fiercebiotech.com) [edit]